Advanced search
Publication Cover
Acta Cardiologica Volume 79, 2024 - Issue 2
Submit an article Journal homepage
60
Views
1
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Tumour necrosis factor-alpha serum level is an independent predictor of medium-term all-cause mortality after transcatheter aortic valve replacement

Jeroen Walpota Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium;b Department of Cardiology, ZorgSaam Hospital, Terneuzen, The Netherlands
,
Paul van Hercka Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium
,
Valerie Collasc Faculty of Health Sciences and Medicine, University of Antwerp, Wilrijk, Belgium
,
Caroline M. Van de Heyninga Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium;c Faculty of Health Sciences and Medicine, University of Antwerp, Wilrijk, Belgium
,
Tom Vandendriesschea Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium
,
Hein Heidbuchela Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium;c Faculty of Health Sciences and Medicine, University of Antwerp, Wilrijk, Belgium
,
Inez Rodrigusd Department of Cardiac Surgery, University Hospital Antwerp, Antwerp, Belgium
&
Johan Bosmansa Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium;e Faculty of Biomedical Sciences, University of Antwerp, Wilrijk, BelgiumCorrespondence[email protected]
 show all
Pages 114-122 | Received 19 Aug 2022, Accepted 31 May 2023, Published online: 20 Feb 2024

References

  • Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561–632. doi: 10.1093/eurheartj/ehab395.
  • Mack MJ. Risk scores for predicting outcomes in valvular heart disease: how useful? Curr Cardiol Rep. 2011;13(2):107–112. doi: 10.1007/s11886-010-0167-9.
  • Compagnone M, Moretti C, Marcelli C, et al. Surgical risk scores applied to transcatheter aortic valve implantation: friends or foes? Short-Term and Long-Term outcomes from a Single-Center registry. J Invasive Cardiol. 2019;31(10):E282–E288.
  • Rosa VEE, Lopes AdS, Accorsi TAD, et al. EuroSCORE II and STS as mortality predictors in patients undergoing TAVI. Rev Assoc Med Bras. 2016;62(1):32–37. doi: 10.1590/1806-9282.62.01.32.
  • Johansson M, Nozohoor S, Zindovic I, et al. Prediction of 30-day mortality after transcatheter aortic valve implantation: a comparison of logistic EuroSCORE, STS score, and EuroSCORE II. J Heart Valve Dis. 2014;23(5):567–574.
  • Piazza N, Wenaweser P, van Gameren M, et al. Relationship between the logistic EuroSCORE and the society of thoracic surgeons predicted risk of mortality score in patients implanted with the CoreValve ReValving system–a Bern-Rotterdam study. Am Heart J. 2010;159(2):323–329. doi: 10.1016/j.ahj.2009.11.026.
  • Cattaneo S, Lagrotta M. Transcatheter implantation of an aortic valve: anesthesiological management. Minerva Anestesiol. 2010;76(4):287–289.
  • Shimura T, Yamamoto M, Kano S, et al. Impact of frailty markers on outcomes after transcatheter aortic valve replacement: insights from a japanese multicenter registry. Ann Cardiothorac Surg. 2017;6(5):532–537. doi: 10.21037/acs.2017.09.06.
  • Afilalo J, Lauck S, Kim DH, et al. Frailty in older adults undergoing aortic valve replacement. J Am Coll Cardiol. 2017;70(6):689–700. doi: 10.1016/j.jacc.2017.06.024.
  • Foldyna B, Troschel FM, Addison D, et al. Computed tomography-based fat and muscle characteristics are associated with mortality after transcatheter aortic valve replacement. J Cardiovasc Comput Tomogr. 2018;12(3):223–228. doi: 10.1016/j.jcct.2018.03.007.
  • Mamane S, Mullie L, Piazza N, et al. Psoas muscle area and All-Cause mortality after transcatheter aortic valve replacement: the Montreal-Munich study. Can J Cardiol. 2016;32(2):177–182. doi: 10.1016/j.cjca.2015.12.002.
  • Saji M, Lim DS, Ragosta M, et al. Usefulness of psoas muscle area to predict mortality in patients undergoing transcatheter aortic valve replacement. Am J Cardiol. 2016;118(2):251–257. doi: 10.1016/j.amjcard.2016.04.043.
  • Merdler I, Frydman S, Sirota S, et al. Neutrophil-to-Lymphocyte ratio as a prognostic marker in transcatheter aortic valve implantation (TAVI) patients. Isr Med Assoc J. 2022;24(4):229–234. http://www.ncbi.nlm.nih.gov/pubmed/35415981
  • Hoffmann J, Mas-Peiro S, Berkowitsch A, et al. Inflammatory signatures are associated with increased mortality after transfemoral transcatheter aortic valve implantation. ESC Heart Fail. 2020;7(5):2597–2610. doi: 10.1002/ehf2.12837.
  • Sousa ALS, Carvalho LAF, Salgado CG, et al. C-reactive protein as a prognostic marker of 1-Year mortality after transcatheter aortic valve implantation in aortic stenosis. Arq Bras Cardiol. 2021;117(5):1018–1027. doi: 10.36660/abc.20190715.
  • Walpot J, Van Herck P, Collas V, et al. Adiponectin serum level is an independent and incremental predictor of all-cause mortality after transcatheter aortic valve replacement. Clin Cardiol. 2022;45(10):1060–1069.
  • Walpot J, Van Herck P, Collas V, et al. Computed tomography measured psoas muscle attenuation predicts mortality after transcatheter aortic valve implantation. J Cardiovasc Med. 2022;23(1):60–68. doi: 10.2459/JCM.0000000000001234.
  • Kalińczuk Ł, Zieliński K, Chmielak Z, et al. Effect on mortality of systemic thromboinflammatory response after transcatheter aortic valve implantation. Am J Cardiol. 2019;124(11):1741–1747. doi: 10.1016/j.amjcard.2019.08.036.
  • Monosilio S, Filomena D, Cimino S, et al. Prognostic value of systemic inflammatory response syndrome after transcatheter aortic valve implantation. J Cardiovasc Med (Hagerstown). 2022;23(6):394–398. doi: 10.2459/JCM.0000000000001309.
  • Rettig TCD, Rigter S, Nijenhuis VJ, et al. The systemic inflammatory response syndrome predicts short-term outcome after transapical transcatheter aortic valve implantation. J Cardiothorac Vasc Anesth. 2015;29(2):283–287. doi: 10.1053/j.jvca.2014.10.005.
  • Krumsdorf U, Chorianopoulos E, Pleger ST, et al. C-reactive protein kinetics and its prognostic value after transfemoral aortic valve implantation. J Invasive Cardiol. 2012;24(6):282–286.
  • Sinning J-M, Scheer A-C, Adenauer V, et al. Systemic inflammatory response syndrome predicts increased mortality in patients after transcatheter aortic valve implantation. Eur Heart J. 2012;33(12):1459–1468. doi: 10.1093/eurheartj/ehs002.
  • Navaratnarajah A, Bhan A, Alcock E, et al. Systemic inflammation and oxidative stress contribute to acute kidney injury after transcatheter aortic valve implantation. Cardiol J. 2020;29(5):824–835. doi: 10.5603/CJ.a2020.0169.
  • Sulženko J, Toušek P, Kočka V, et al. Degenerative changes and immune response after transcatheter aortic valve implantation. Comparison with surgical aortic valve replacement. J Cardiol. 2017;69(2):483–488. doi: 10.1016/j.jjcc.2016.03.009.
  • Mirna M, Holnthoner M, Topf A, et al. Tumor necrosis factor alpha—an underestimated risk predictor in patients undergoing transcatheter aortic valve replacement (TAVR)? J Clin Lab Anal. 2021;35(11):e23977. doi: 10.1002/jcla.23977.
  • Katsiki N, Mantzoros C, Mikhailidis DP. Adiponectin, lipids and atherosclerosis. Curr Opin Lipidol. 2017;28(4):347–354. doi: 10.1097/MOL.0000000000000431.
  • Rosenhek R, Baumgartner H. Aortic sclerosis, aortic stenosis and lipid-lowering therapy. Expert Rev Cardiovasc Ther. 2008;6(3):385–390. doi: 10.1586/14779072.6.3.385.
  • Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49(5):554–561. doi: 10.1016/j.jacc.2006.07.072.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.